Filing Details
- Accession Number:
- 0001415889-24-029028
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-11 19:56:44
- Reporting Period:
- 2024-12-09
- Accepted Time:
- 2024-12-11 19:56:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750284 | Olema Pharmaceuticals Inc. | OLMA | Pharmaceutical Preparations (2834) | 300409740 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1831410 | Cyrus Harmon | C/O Olema Pharmaceuticals, Inc. 780 Brannan St San Francisco CA 94103 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-12-09 | 29,250 | $0.00 | 780,533 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-12-10 | 8,256 | $9.37 | 772,277 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-12-11 | 7,958 | $8.66 | 764,319 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-12-11 | 179 | $9.39 | 764,140 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 122,028 | Indirect | See Footnote |
Footnotes
- On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria.
- The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- The weighted average sale price for the transaction reported was $9.37, and the range of prices was between $8.89 and $9.70. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.
Billionaire Hedge Funds
